The purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

The purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(CSII)(1.CSII alone; 2.liraglutide combined with CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

Inclusion Criteria:

• newly diagnosed type 2 diabetes
• fasting blood glucose (FBG) level ranging from 7.0-16.7mmol/L
• body mass index (BMI) ranging from 21-35kg/m2
• antihypercaemic and antihyperlipidemic medication-naive patients

Exclusion Criteria:

• having any severe acute or chronic diabetic complications
• renal dysfunction, blood creatinine>150umol/L
• blood aminotransferase level rising up(more than 2 times of the upper normal limit of ALT)
• any severe cardiac disease including congestive cardiac failure, unstable angina or myocardial infarct in 12 months
• chronic or acute pancreatic disease
• severe systemic diseases or malignant tumor
• female patients incline to be pregnant
• being treated with corticosteriod, immunosuppressing drugs or cytotoxic drugs
• poor compliance